Cytokinetics (FRA:KK3A) Short-Term Capital Lease Obligation : €16.77 Mil (As of Mar. 2024)

View and export this data going back to 2004. Start your Free Trial

What is Cytokinetics Short-Term Capital Lease Obligation?

Cytokinetics's Short-Term Capital Lease Obligation for the quarter that ended in Mar. 2024 was €16.77 Mil.

Cytokinetics's quarterly Short-Term Capital Lease Obligation increased from Sep. 2023 (€16.15 Mil) to Dec. 2023 (€16.41 Mil) and increased from Dec. 2023 (€16.41 Mil) to Mar. 2024 (€16.77 Mil).

Cytokinetics's annual Short-Term Capital Lease Obligation declined from Dec. 2021 (€13.15 Mil) to Dec. 2022 (€12.11 Mil) but then increased from Dec. 2022 (€12.11 Mil) to Dec. 2023 (€16.41 Mil).

Cytokinetics Short-Term Capital Lease Obligation Historical Data

The historical data trend for Cytokinetics's Short-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cytokinetics Short-Term Capital Lease Obligation Chart

Cytokinetics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Short-Term Capital Lease Obligation

Get a 7-Day Free Trial

4.15

2.29

13.15

12.11

16.41

Cytokinetics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Short-Term Capital Lease Obligation	Get a 7-Day Free Trial															13.32	14.49	16.15	16.41	16.77

Cytokinetics Short-Term Capital Lease Obligation Explanation

Short-Term Capital Lease Obligation represents the total amount of Long-Term Capital Lease Obligation that must be paid within the next accounting period. Capital lease obligations are contractual obligations that arise from obtaining the use of property or equipment via a capital lease contract.

Cytokinetics Short-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Cytokinetics's Short-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

Cytokinetics (FRA:KK3A) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cytokinetics Inc (FRA:KK3A) » Definitions » Short-Term Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

CYTK:USA

Address

350 Oyster Point Boulevard, South San Francisco, CA, USA, 94080

Website

https://www.cytokinetics.com

Cytokinetics Inc is a biotechnology company that develops muscle biology-driven treatments for diseases characterized by reduced muscle function, muscle weakness, and fatigue. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary disease. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.

Cytokinetics (FRA:KK3A) Headlines

No Headlines